Categories
Tags
Abbott Advertising AstraZeneca Barack Obama Big Pharma Biotechnology and Pharmaceuticals Bristol Myers Squibb business Cancer Clinical trial conference Deal Eli Lilly European Commission European Union Facebook FDA Food and Drug Administration Genentech generics GlaxoSmithKline Google GSK HBA Health Health care Johnson & Johnson layoffs Lilly Marketing Merck Novartis Pfizer Pharma Pharmaceutical drug pharmaceutical industry Research and development Roche Sanofi-Aventis Schering Plough social media Twitter U.S. Food and Drug Administration United States Wyeth
Technology News
BioPharm News

Live From ePharma Summit 2008: Benchmarketing e-Marketing
The bottom line:
Here are some key benchmark figures from ComScore’s study:
Does this mean banner ads are a dead issue? Hardly, according to Petrini. “You absolutely have to have banners, because they have a latency effect on getting people to recall,” she said. “Even if they didn’t click through on the spot, people who have been exposed to display banners are likely to search for a drug at a later time.”